EdgarLookup

Khan Najat

Insider transactions at 1 company

This page shows all SEC Form 4 filings attributed to Khan Najat. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.

RXRX
Company Title Type Shares Price Value Date
RXRX Chief R&D Commercial Officer Sale 124,403 $4.41 $548,617 Dec 22, 2025
RXRX Chief R&D Commercial Officer Tax Withholding 17,584 $4.14 $72,798 Nov 17, 2025
RXRX Chief R&D Commercial Officer Award / Grant 84,925 Nov 5, 2025
RXRX Chief R&D Commercial Officer Sale 36,599 $5.52 $202,026 Aug 15, 2025
RXRX Chief R&D Commercial Officer Tax Withholding 3,796 $4.25 $16,133 May 15, 2025
RXRX Chief R&D Commercial Officer Award / Grant 8,049 Feb 3, 2025
RXRX Chief R&D Commercial Officer Award / Grant 496,972 Aug 1, 2024